Pharming confirms anticipated call from public bondholders to exercise put option
(Thomson Reuters ONE) -
Leiden, The Netherlands, October 12, 2010. Pharming Group NV ("Pharming" or
"the Company") (NYSE Euronext: PHARM) today confirms the anticipated exercise of
the put option by the 2007 public bondholders to repay the remaining outstanding
2007 convertible bonds per 31 October 2010. The Company has sufficient cash
available to repay the ?10.9 million nominal bonds plus the final semi-annual
?0.4 million interest and to continue operations into 2011.
Dr. Sijmen de Vries, Chief Executive Officer of Pharming: "We are very pleased
that, as anticipated, we are now able to close the book on, and pay-off this
debt. We can now focus on building and on executing our plans to financial
sustainability."
About Pharming Group NV
Pharming Group NV is developing innovative products for the treatment of genetic
disorders, specialty products for surgical indications, and nutritional
products. On June 24, the European Medicines Agency adopted a positive opinion
for Ruconest(TM) (Rhucin® in non-EU territories) for the treatment of angioedema
attacks. Market Authorization in the European Economic Area is therefore
expected imminently with an anticipated market launch in the fourth quarter
2010. The product is also under development for follow-on indications, i.e.
antibody-mediated rejection (AMR) and delayed graft function (DGF) following
kidney transplantation. The advanced technologies of the Company include
innovative platforms for the production of protein therapeutics, technology and
processes for the purification and formulation of these products. Additional
information is available on the Pharming website,www.pharming.com.
This press release contains forward looking statements that involve known and
unknown risks, uncertainties and other factors, which may cause the actual
results, performance or achievements of the Company to be materially different
from the results, performance or achievements expressed or implied by these
forward looking statements.
Contact:
Marjolein van Helmond, T: +31 (0)71 52 47 431 or +31 (0)6 109 299 54
[HUG#1450964]
Press release (PDF):
http://hugin.info/132866/R/1450964/392187.pdf
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Pharming Group N.V. via Thomson Reuters ONE
Unternehmensinformation / Kurzprofil:
Datum: 12.10.2010 - 08:00 Uhr
Sprache: Deutsch
News-ID 45099
Anzahl Zeichen: 0
contact information:
Town:
Leiden
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 199 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Pharming confirms anticipated call from public bondholders to exercise put option"
steht unter der journalistisch-redaktionellen Verantwortung von
Pharming Group N.V. (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
